Cargando…
Ipilimumab-Induced Neutropenia in Melanoma
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia followin...
Autores principales: | Ban-Hoefen, Makiko, Burack, Richard, Sievert, Lynn, Sahasrabudhe, Deepak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984314/ https://www.ncbi.nlm.nih.gov/pubmed/27570779 http://dx.doi.org/10.1177/2324709616661835 |
Ejemplares similares
-
Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014) -
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
por: Wei, Guoqing, et al.
Publicado: (2012) -
Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016) -
Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
por: Azmat, Umal, et al.
Publicado: (2016) -
Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma
por: Mohan, Shalini V., et al.
Publicado: (2016)